If you’re running a privately held biotech, the time to go public is now. Clinical data already in hand or not, biotechs have charged to Wall Street at a record pace over the past two weeks, raising more than $1 billion in offerings that all met or exceeded their projected valuations. And there are no signs of slowing down-six more just recently joined the queue, many of them without scant, if any evidence, in humans, their drugs work. That’s great news for early stage life sciences investors and the overall health of the startup biotech ecosystem. But it also sets up… Read more »
UNDERWRITERS AND PARTNERS